C WorldWide Group’s Royalty Pharma RPRX Stock Holding History

C WorldWide Group’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.5M	Sell	471,881 -189,895	-29%	-$9.88M	0.64%	26
2026 Q1	$31.7M	Sell	661,776 -38,685	-6%	-$1.69M	0.68%	21
2025 Q4	$27.1M	Buy	700,461 +46,004	+7%	+$1.75M	0.47%	27
2025 Q3	$23.1M	Buy	654,457 +27,089	+4%	+$981K	0.36%	34
2025 Q2	$22.6M	Buy	627,368 +181,530	+41%	+$6.01M	0.31%	33
2025 Q1	$13.9M	Buy	+445,838	New	+$14.1M	0.17%	49

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIA

Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

C WorldWide Group's RPRX Position: Q2 2026 in Review

C WorldWide Group reduced its Royalty Pharma (RPRX) stake by 29% in Q2 2026, selling an estimated $9.88M and leaving 471,881 shares worth $26.5M. The position accounts for 0.64% of the portfolio, ranked #26.

C WorldWide Group first reported a position in RPRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $31.7M in Q1 2026. 565 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

C WorldWide Group held 471,881 shares of Royalty Pharma worth $26.5M as of Q2 2026.
C WorldWide Group sold 189,895 Royalty Pharma shares in Q2 2026, an estimated $9.88M.
Royalty Pharma made up 0.64% of C WorldWide Group's portfolio in Q2 2026, its #26 holding.
C WorldWide Group first reported a position in Royalty Pharma in Q1 2025 and has held it in 6 quarters since.
C WorldWide Group's Royalty Pharma position peaked at $31.7M in Q1 2026.
565 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on C WorldWide Group's 13F filing for Q2 2026, filed 4 Aug 2026.